ArticleDrug design, development and therapy2026
For Advanced Oesophageal Squamous Cell Carcinoma, PD-1 Antibody Combined with Chemotherapy Improves Progression-Free Survival Compared with Monotherapy or Chemotherapy Alone as First-Line Treatment: A Retrospective Study with Prognostic Biomarker Analysis.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oesophageal squamous cell carcinoma (OSCC) accounts for >90% of oesophageal cancer cases in China, with most patients diagnosed at an advanced stage and poor prognosis. Real-world comparative data on first-line chemotherapy, PD-1 monotherapy, and their combination remain limited. Objective: To evaluate the efficacy and safety of first-line camrelizumab plus nab-paclitaxel and cisplatin versus PD-1 monotherapy or chemotherapy alone in advanced OSCC, and to identify prognostic peripheral blood biomarkers. Methods: Retrospective analysis of 253 patients (combination, n=68; PD-1 monotherapy, n=77; chemotherapy alone, n=108). Progression-free survival (PFS) was compared by Log rank test; objective response rate (ORR) and disease control rate (DCR) by chi-square; independent prognostic factors by Cox regression. Results: ORR/DCR did not differ significantly among groups (P>0.05). Adverse events included vomiting, cytopenias, and fatigue; grade 1-2 anaemia was higher in combination vs monotherapy (76.5% vs 29.9%, P<0.001), and neutropenia higher in combination vs chemotherapy alone (72.1% vs 49.1%, P=0.002). Median overall survival was longest in the combination group (12.0 months) versus monotherapy (6.0 months) and chemotherapy alone (9.0 months). PFS differed significantly across all groups (all P<0.001). Poorly differentiated tumours, elevated NLR (≥5), and higher BMI were independent prognostic factors. Conclusion: First-line camrelizumab-based combination significantly improves PFS with manageable toxicity; NLR is a readily available independent biomarker, supporting this regimen as a preferred option and aiding patient selection in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.